Evidence map›Paper›PMID 40545000›Full record

ReviewTransplantation and cellular therapy2025

Assessing physical function in transplantation and CAR-T recipients: expert recommendations from the survivorship, aging and biobehavioral special interest groups of ASTCT.

Shatha Farhan, Vanessa E Kennedy, Manuel R Espinoza-Gutarra, Hannah Lust, Maria Silvina Odstrcil Bobillo, Adam Yuh Lin, Rebecca L Olin, Richard J Lin, Kelly E Rentscher, Mallory R Taylor and 13 more

Abstract readReview
In one paragraph

Review in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shatha FarhanStem Cell Transplant & Cellular Therapy Program, Henry Ford Health, Detroit, Michigan. Electronic address: sfarhan1@hfhs.org.
Vanessa E KennedyDivision of Blood and Marrow Transplant and Cellular Therapy, Stanford University, Stanford, California.
Manuel R Espinoza-GutarraO'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama.
Hannah LustAnn & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Maria Silvina Odstrcil BobilloHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Adam Yuh LinRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
Rebecca L OlinUniversity of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, CA.
Richard J LinMemorial Sloan Kettering Cancer Center, New York City, New York.
Kelly E RentscherDepartment of Psychiatry and Behavioral Medicine, MCW Cancer Center Scholar, Medical College of Wisconsin, Milwaukee, Wisconsin.
Mallory R TaylorBen Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, Washington.
Lathika MohanrajSchool of Nursing, Virginia Commonwealth University and VCU Massey Comprehensive Cancer Center, Richmond, Virginia.
William A WoodDepartment of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Hemant S MurthyDivision of Hematology/Oncology, Mayo Clinic Florida, Jacksonville, Florida.
Nuasheen AhmedDivision of Hematological Malignancies and Cellular Therapeutics, Department of Internal Medicine, US.
Amylou C DueckMayo Clinic, Scottsdale, Arizona.
Rachel PhelanDepartment of Pediatrics, Division of Hematology/Oncology/Blood and Marrow Transplantation, Medical College of Wisconsin, Milwaukee, Wisconsin.
Debra Lynch KellyLoewenberg College of Nursing, University of Memphis, Memphis, Tennessee.
Carrie YuenHematology and oncology, Neal Cancer Center, Houston Methodist Hospital, Houston, Texas.
Pashna N MunshiCell Therapy and Transplant, University of Pennsylvania, Philadelphia, Pennsylvania.
Hélène SchoemansDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium; department of Public Health and Primary Care, ACCENT VV, KU Leuven - University of Leuven, Leuven, Belgium.
Betty K HamiltonDepartment of Hematology/Oncology, Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio.
Catherine LeeClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Anthony D SungDivision of Hematological Malignancies and Cellular Therapeutics, Department of Internal Medicine, US.

Funding

CTSA K12 Program at StanfordK12TR004930 · NCATS · STANFORD UNIVERSITY · PI STEVEN M. ASCH, Eleni Linos · 2024 to 2026
$4.2M
Accelerated biological and phenotypic aging in hematopoietic cell transplant survivors: Social support as a protective factorK01AG065485 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RENTSCHER, KELLY E · 2020 to 2024
$600k
NCATS NIH HHS K12 TR004930NIA NIH HHS K01 AG065485
6 · The paper itself

Abstract

The past few decades have witnessed significant advancements in stem cell transplantation and cell therapy (TCT). This has allowed their expanded use in older patients and those with comorbidities with favorable outcomes. However, these procedures carry significant risks, such as graft-versus-host disease, infection, cytokine release syndrome, and immune effector cell-associated neurotoxicity. Therefore, physical function assessment is crucial to assess patient fitness and potential optimization before and after TCT. The existence of diverse assessment tools makes implementation, comparison, and sharing knowledge among centers difficult. This paper proposes a tiered approach aiming to harmonize physical assessment in the TCT. This allows healthcare facilities to prioritize recommended assessments based on their current capabilities and resources. TCT patients should receive comprehensive physical assessments pre- and post-TCT using a combination of both patient-reported and objective measures. For patient-reported measures, the Patient-Reported Outcomes Measurement Information System should be considered. For objective measures, we recommend considering a physical performance assessment (eg, gait speed) or muscle strength assessment (eg, hand grip), if feasible. Albumin and C reactive protein are also informative in predicting the risk of nonrelapse mortality. Other composite tools, questionnaire libraries, biomarkers, imaging, and wearables can be added according to research and clinical needs. A care workflow needs to be in place in case any impairment is found during the evaluation with goals of increasing physiologic reserve and mitigating stressors. This tiered approach will increase awareness and adoption of these tools and hence improve patient care, facilitate data sharing, and enhance collaboration in this field.

Indexed as

Immunotherapy, AdoptivePhysical Functional PerformanceStem Cell TransplantationAgingGraft vs Host DiseaseHumansSurvivorshipCAR-T therapyPhysical functionStem cell transplantation

Identifiers

PMID40545000
PMCPMC13189036

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.